Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant

DNLI-E-0008

Une extension en ouvert pour étudier la sécurité, la tolérance et l'efficacité à long terme de dnl310 chez les patients atteints de mucopolysaccharidose de type ii (mps ii) à partir de l'étude dnli-e-0002 ou de l'étude dnli-e-0007
Source : traduction non-officielle opérée par intelligence artificielle
voir le texte original

An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

open-label extension
OLE
safety
tolerability
efficacy
long-term treatment
DNL310
central nervous system
CNS
enzyme-replacement therapy
ERT
for mucopolysaccharidosis type II (MPS II; Hunter syndrome)
DNLI-E-0002
DNLI-E-0007.
Source : Importé depuis le centre
Pédiatrie
Recrutement ouvert
Dernière modification : 2025/04/23
Type de recherche

Interventionnel

Médicament expérimental

Phase II/III


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Pédiatrie

Profil des participants

Sexe(s) des participants

Hommes

Femmes

Aptitude des participants

Mineurs

Critères de sélection

Critères d'inclusion

1. Have written informed consent by the parent(s) or LAR and participant consent/assent as required based on local regulations, IRB/IEC requirements, and participant age
2. Parent(s) or LAR and participant willing and able to comply with study visits, procedures, and restrictions as required based on local regulations, IRB/IEC requirements, and participant age
3. For participants from Study DNLI-E-0002 only: Completed at least through the Week 49 visit in Study DNLI-E-0002 and did not discontinue study intervention early
4. For participants from Study DNLI-E-0007 only: Completed the treatment period of 96 weeks in Cohort A for nMPS II participants and 48 weeks in Cohort B for nnMPS II participants 5. For participants with hearing impairment who require hearing aids: Participant and parent(s) or LAR agree to make every effort to comply with the use of functioning hearing aid(s) before neurocognitive assessments, and parent(s)/LAR agree to encourage the participant to wear them during the study and on neurocognitive testing days.
6. When engaging in sex with a female partner of childbearing potential, both the male participant and the female partner must use contraception consisting of two forms of birth control, one of which must be a male barrier method such as a latex or polyurethane condom (not considered highly effective), and the other of which must be a highly effective method (male or female; see Section 10.6.2), from start of dosing throughout the clinical study period, and for 90 days after the final administration of study intervention.
7. Female participants of childbearing potential must have established use of hormonal methods of contraception (oral, injected, implanted, or transdermal for at least 3 months prior to Week 1) or an intrauterine device alone or in combination with a barrier method (condom, diaphragm, or cervical/vault cap supplemented with spermicidal foam/gel/film/cream/suppository), or a double-barrier method. Individually, hormonal, barrier, spermicidal, or intrauterine device methods alone are not acceptable (Section 10.6.2), and pregnancy must be avoided for 28 days after the last dose of study intervention. Female participants of nonchildbearing potential at enrollment who may reach menarche during the study must also agree to the above use of contraception should they reach menarche during the study.

Source : Importé depuis le centre
Critères d'exclusion

1. Have unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities based on medical history, baseline laboratory values, ECGs, or other baseline procedures that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments
2. Have a positive pregnancy test at baseline
3. Have any other issue that, in the opinion of the investigator, would make the participant ineligible for study participation

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Intervention

DNL310

Source : Importé depuis le centre
Cohortes
Donnée non disponible
Données à jour depuis : 23 avril 2025

Description de l'étude

Donnée non disponible

Sites

Centres participants

    1 centres
  • CENTRE UNIVERSITAIRE DE SANTÉ MCGILL * **

    Montréal

    QUÉBEC, CANADA

    Recrutement local
    État du recrutement: OUVERT
    Contacts locaux
    chercheurs:
    • J. Mitchell

    co-chercheurs:
    • A. Sbrocchi

    • G. BERNARD

    cliquez ici pour plus d'informations pour ce centre
    Cohortes
    Centre universitaire de santé McGill
    Donnée non disponible
    Données à jour depuis : 23 avril 2025

Dernière modification : 23 avril 2025
Données à jour depuis : 23 avr.
Origine des données : Nagano
Référence Nagano: 2024-10143